Navigation Links
New Drug May Help Patients With Irregular Heartbeat Avoid Stroke
Date:2/11/2011

By Kathleen Doheny
HealthDay Reporter

THURSDAY, Feb. 10 (HealthDay News) -- A new anti-clotting drug works better than aspirin for stroke prevention in some patients with the common, sometimes lethal, heart rhythm problem known as atrial fibrillation, according to research presented Thursday.

The new drug, apixaban, is not yet approved for use by the U.S. Food and Drug Administration. But study co-author Dr. Hans-Christoph Diener said the pill "reduced stroke risk [in patients with atrial fibrillation] by 55 percent, compared to aspirin." He believes that "the results of this clinical trial will change clinical practice."

Diener, of the department of neurology and the Stroke Center at University Hospital Essen in Germany, presented the findings at the annual meeting of the American Stroke Association's International Stroke Conference in Los Angeles. The findings are also published online Feb. 10 in the New England Journal of Medicine.

In atrial fibrillation, an irregular beating of the heart causes blood to pool in the heart's chambers. The heart can then "throw" clots up into the arteries supplying blood to the brain, greatly raising the risks for stroke.

Patients with atrial fibrillation are typically prescribed anticoagulants such as warfarin, which is notoriously hard to manage, Diener said at a news conference announcing the study results.

Anticoagulants taken orally can decrease stroke risk by up to 70 percent, according to Diener, but many patients don't comply with the regimen. "About half of all patients refuse to take [warfarin]," he noted, because its use is accompanied by dietary restrictions and the need for frequent blood tests to check blood levels of the drug. Some patients also fear the possibility of a known hazard of warfarin, an excess risk for bleeding.

Many patients who can't or won't take warfarin do take daily aspirin, which cuts the odds of stroke in atrial fibrillation by about 20 percent, according to background information in the study.

In the new study of apixaban, researchers assigned almost 5,600 patients with atrial fibrillation and an increased risk of stroke (due to age or prior stroke, for instance) to one of two groups: apixaban, at 5 milligrams taken twice daily; or aspirin, with doses ranging from 81 to 324 milligrams per day.

The study was done at 522 centers in 36 countries from late 2007 to late 2009. The researchers wanted to compare which drug was better at preventing stroke or blockages due to blood clots elsewhere in the body, called systemic embolism.

Among patients on apixaban, there were 51 strokes or embolisms, or 1.6 percent per year, compared to 113 such events, or 3.7 percent, among those on aspirin.

While apixaban patients experienced 44 major bleeding events, aspirin takers had 39, but the difference was not great enough to be significant from a statistical point of view, Diener said.

The study was funded by Bristol-Myers Squibb and Pfizer, who are working jointly to develop apixaban.

The drug has been shown in previous research to be better at preventing dangerous leg blood clots and lung clots after hip replacement surgery than an older drug, enoxaparin.

Apixaban works by blocking a crucial step in the formation of blood clots. The study of the drug's effects on stroke prevention was actually halted early after one year, Diener said, because of the huge difference found between the two drugs and the superiority of apixaban.

The new drug isn't yet approved by the FDA and Diener couldn't predict when that might happen. Results of another study, a head-to-head comparison of apixaban against warfarin, is due out in August, he said.

A 55 percent reduction in stroke risk compared to aspirin is impressive, said Dr. Larry Chinitz, professor of medicine at the New York University School of Medicine and director of the Heart Rhythm Center at NYU Langone Medical Center. He reviewed the study findings but was not involved in the research.

"I think it's a game-changer" for higher risk patients with atrial fibrillation, he said, such as those over age 70.

The new drug, if approved, ''will certainly improve the lifestyle of patients," Chinitz said, as it won't require, as warfarin does, frequent blood tests or dietary restriction.

Another new anti-clotting drug, Pradaxa (dabigatran), was approved by the FDA in October 2010 for stroke prevention in those with atrial fibrillation. It inhibits an enzyme involved in blood clotting.

More information

To learn stroke's warning signs, head to the American Stroke Association.

SOURCES: Hans-Christoph Diener, M.D., professor and chairman, department of neurology and Stroke Center, University Hospital Essen, Essen, Germany; Larry Chinitz, M.D., director, Heart Rhythm Center, NYU Langone Medical Center, and professor, medicine, NYU School of Medicine, New York City; Feb. 10, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few Stroke Patients Given Clot-Buster Quickly Enough: Study
2. Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinsons disease
3. Everolimus improves progression-free survival for patients with rare pancreatic cancer
4. Researchers: Elderly patients 4 times more likely to die from treatment complications
5. Using pharmacist-directed service improves quality of care for patients
6. Improving care for bowel cancer patients
7. Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
8. Researchers Craft Blood Vessels for Heart, Kidney Patients
9. Prehabilitation better prepares patients for knee replacement surgery
10. For-Profit Hospices May Prefer Certain Types of Patients: Study
11. Will Loss of Lethal Injection Drug Harm Surgical Patients?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Help Patients With Irregular Heartbeat Avoid Stroke
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... your life? The answer may be at the tips of your toes. Foot massage, ... benefits as well as pure comfort and relaxation. The American Board of Multiple ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... ... , ... Colorize is a web theme package created exclusively for ... Colorize's dynamic moving camera. Colorize is perfect for personal and web related videos and ... 1 to 5 focus points per scene, stage floor scene presets that are great ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) ... Chronic Obstructive Pulmonary Disease (COPD) is a ... airways and lungs. Persistent breathing difficulties and repeated ... of the leading causes of morbidity and the ... is linked to cumulative exposure to risk factors, ...
(Date:2/4/2016)... ALBANY, N.Y. , Feb. 4, 2016  AMRI (NASDAQ: ... Vice President of Pfizer Inc. and President of Pfizer Global ... effective as of February 4, 2016. In addition, the Company ... member of the audit committee since 2010, has retired from ... time and attention to his other business ventures.  ...
Breaking Medicine Technology: